Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men
Hughes L, Ruth K, Rebbeck T, Giri V. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer And Prostatic Diseases 2013, 16: 308-314. PMID: 24061634, PMCID: PMC3865712, DOI: 10.1038/pcan.2013.36.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramAfrican American menHigh-risk menCC/CTProstate cancerCancer diagnosisIL-16Family historyProstate cancer screening strategiesProstate cancer risk assessmentCancer Risk Assessment ProgramIL-16 genotypesLongitudinal screening programCancer screening strategiesProstate cancer screeningTaqMan SNP genotyping assaysProstate cancer developmentPersonalized risk estimatesAfrican AmericansCancer risk assessmentGenetic variantsHazard ratioSNP genotyping assaysCancer screeningScreening programValidation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer
Chang B, Hughes L, Chen D, Gross L, Ruth K, Giri V. Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer. BJU International 2013, 113: e150-e156. PMID: 23937305, PMCID: PMC3830710, DOI: 10.1111/bju.12264.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramHigh-risk groupPSA levelsCaucasian manProstate cancerFamily historyProstate cancer screening strategiesProstate cancer screening studyCancer Risk Assessment ProgramBaseline PSA levelsTaqMan single nucleotide polymorphismCancer screening strategiesCancer screening studySingle nucleotide polymorphismsAfrican American ethnicityAllele carrier statusBRCA gene mutationsPotential confoundersAge 35Eligibility criteriaClinical relevanceT alleleRisk assessment programA alleleCarrier status